4//SEC Filing
Syros Pharmaceuticals, Inc. 4
Accession 0001104659-16-131409
CIK 0001556263operating
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 6:02 AM ET
Size
28.5 KB
Accession
0001104659-16-131409
Insider Transaction Report
Form 4
Arch Venture Fund VII LP
10% Owner
Transactions
- Conversion
Common Stock
2016-07-06+266,666→ 479,999 total - Conversion
Common Stock
2016-07-06+2,000,000→ 3,813,332 total - Conversion
Series A-1 Preferred Stock
2016-07-06−1,000,000→ 0 total→ Common Stock (266,666 underlying) - Conversion
Series A-2 Preferred Stock
2016-07-06−5,000,000→ 0 total→ Common Stock (1,333,333 underlying) - Conversion
Common Stock
2016-07-06+1,333,333→ 1,813,332 total - Conversion
Common Stock
2016-07-06+423,805→ 4,237,137 total - Purchase
Common Stock
2016-07-06$12.50/sh+400,000$5,000,000→ 4,637,137 total - Conversion
Series A-3 Preferred Stock
2016-07-06−7,500,000→ 0 total→ Common Stock (2,000,000 underlying) - Conversion
Series B Preferred Stock
2016-07-06−1,589,269→ 0 total→ Common Stock (423,805 underlying)
Footnotes (5)
- [F1]The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F3]The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F4]The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F5]These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001556263
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 6:02 AM ET
- Size
- 28.5 KB